Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌体节，防绝经后骨质疏松症药物。